Professor Duncan Maskell has international experience in science and commerce, developed across a 30-year career in research, academia and entrepreneurship. He also has experience across the private sector and was involved in the commercialisation of research initiatives.
Prof Maskell is the vice-chancellor at the University of Melbourne. Prior to that, he was senior pro-vice-chancellor at the University of Cambridge in the UK where he was responsible for planning and resources for the institution's operations.
As a research specialist in infectious diseases, Prof Maskell also held roles at the University of Oxford, Imperial College London and Wellcome Biotech.
Prof Maskell co-founded several biotech companies including Arrow Therapeutics which was sold to biopharmaceutical company AstraZeneca, and Discuva which was sold to Summit Therapeutics.
He was a non-executive director of Genus, a FTSE 250 company.
